|
Post by sportsrancho on Feb 17, 2018 12:22:55 GMT -5
Hellooooo? Sales are up 250-300% in the past 12 months. Share price is up 447% from it’s low in just the past 8 months. What needle are you referring to? Exactly, I feel it, I’m back in the green because of it. Sometimes you have to follow your gut instinct, and there aren’t any guarantees that show up on the surface until later, then you’re looking back thinking darn....I should’ve bought back when this or that happened.....
|
|
|
Post by sayhey24 on Feb 17, 2018 13:44:55 GMT -5
Here we are three years after approval and still less than 500 scripts. Some predicted afrezza was a niche drug and based on these numbers they were right.
While waiting for technology to catch up and everyone walking around with the IWatch/Fitbit/Fossil seeing their BG all the time it has amazed me Mike has never seemed to focus on the one area which seems to have had success.
Why has there not been a more targeted effort to work with specific diabetes practices/clinics? At the grass roots level was it not possible for the MNKD sales guy to get a doctor or two to model a portion of their practice after what VDex is doing? Don't any of these reps know a doctor who would give it a try? If VDex has really had success you would think a zillion doctors would want to have similar success.
What am I missing here? Maybe the VDex model doesn't work or doesn't scale? Otherwise it would seem like a no=brainer to me.
|
|
|
Post by lennymnkd on Feb 17, 2018 13:58:12 GMT -5
Ask myself that everyday , is it that as far as the devices are concerned , they are not ubiquitous enough ! Or is it more data is needed (insurance) to make the whole thing cost effective. Or could it be some big player frightens them /BP ....thinking they will knock them out of the box .
|
|
|
Post by falconquest on Feb 17, 2018 16:01:03 GMT -5
Hellooooo? Sales are up 250-300% in the past 12 months. Share price is up 447% from it’s low in just the past 8 months. What needle are you referring to? Yup, that's awesome. But it really all depends on your reference point doesn't it? Let's compare the share price today to say, $9.00 pre-split. We're at $2.99 now which represents a split adjusted $0.598. Now consider the split adjusted hypothetical $9.00. The share price would have to be $45.00 to be equivalent now. So, $2.99 vs. $45.00. We need a share price increase of $42.01 to get back to that pre-split $9.00 level. I guess if you were smart enough to buy at the absolute bottom then you may be up 447% but I'm guessing most here are still underwater. Sure, being up is nice because it's not declining but there's a lot of real estate between $2.99 and $45.00. Another thing to consider, If you're at 1 and go to 4 you're up 300% but if your goal is say, 5000 scripts per month then 3 or 100 or 500 per month is just scratching the surface isn't it? So playing math percentages is also relevant to your reference isn't it?
|
|
|
Post by mytakeonit on Feb 17, 2018 16:10:51 GMT -5
So going from 4 to 1 means that you're down 75% ... but, going from 1 to 4 you're up 300% So, obviously we are all going up because it makes more sense. Also, the window of opportunity was very small when we were at absolute bottom ... and I was able to get a ton at 82 cents. Thank you ... Thank you ! The applause is deafening. But, instead of clapping ... I'd rather you throw $$$.
|
|